Mark Lebwohl

1.8k total citations
44 papers, 1.2k citations indexed

About

Mark Lebwohl is a scholar working on Immunology, Dermatology and Molecular Biology. According to data from OpenAlex, Mark Lebwohl has authored 44 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Immunology, 20 papers in Dermatology and 11 papers in Molecular Biology. Recurrent topics in Mark Lebwohl's work include Psoriasis: Treatment and Pathogenesis (27 papers), Dermatology and Skin Diseases (10 papers) and Retinoids in leukemia and cellular processes (8 papers). Mark Lebwohl is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (27 papers), Dermatology and Skin Diseases (10 papers) and Retinoids in leukemia and cellular processes (8 papers). Mark Lebwohl collaborates with scholars based in United States, United Kingdom and Canada. Mark Lebwohl's co-authors include John Koo, Stewart B. Siskin, Charles N. Ellis, Wendy W. Lou, Joseph F. Merola, Arthur Kavanaugh, Jashin J. Wu, Robert Gniadecki, Janet H. Prystowsky and Lionel Bercovitch and has published in prestigious journals such as Free Radical Biology and Medicine, Annals of the Rheumatic Diseases and Journal of Investigative Dermatology.

In The Last Decade

Mark Lebwohl

39 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Lebwohl United States 20 787 613 213 194 151 44 1.2k
Tomotaka Mabuchi Japan 20 1.0k 1.3× 638 1.0× 185 0.9× 200 1.0× 132 0.9× 72 1.4k
Slaheddine Marrakchi Tunisia 17 499 0.6× 563 0.9× 160 0.8× 240 1.2× 72 0.5× 44 1.2k
Satveer K. Mahil United Kingdom 18 1.1k 1.4× 675 1.1× 178 0.8× 171 0.9× 179 1.2× 45 1.5k
Marco Galluzzo Italy 22 1.0k 1.3× 720 1.2× 207 1.0× 72 0.4× 212 1.4× 86 1.4k
M. Lahfa France 15 933 1.2× 1.1k 1.7× 204 1.0× 80 0.4× 235 1.6× 22 1.6k
Efterpi Zafiriou Greece 17 495 0.6× 341 0.6× 102 0.5× 108 0.6× 164 1.1× 65 951
Wojciech Baran Poland 14 586 0.7× 388 0.6× 109 0.5× 121 0.6× 122 0.8× 66 967
Inna Cueto United States 18 895 1.1× 936 1.5× 108 0.5× 167 0.9× 247 1.6× 27 1.6k
Nicoletta Bernardini Italy 15 372 0.5× 444 0.7× 104 0.5× 230 1.2× 82 0.5× 83 1.0k
Dagmar Wilsmann‐Theis Germany 19 739 0.9× 677 1.1× 169 0.8× 95 0.5× 155 1.0× 68 1.1k

Countries citing papers authored by Mark Lebwohl

Since Specialization
Citations

This map shows the geographic impact of Mark Lebwohl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Lebwohl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Lebwohl more than expected).

Fields of papers citing papers by Mark Lebwohl

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Lebwohl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Lebwohl. The network helps show where Mark Lebwohl may publish in the future.

Co-authorship network of co-authors of Mark Lebwohl

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Lebwohl. A scholar is included among the top collaborators of Mark Lebwohl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Lebwohl. Mark Lebwohl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Blauvelt, Andrew, et al.. (2025). EVERLAST-A: A Phase 2a Study Design of ORKA-001, a Novel Half-Life Extended IL-23p19 Monoclonal Antibody for Plaque Psoriasis. SKIN The Journal of Cutaneous Medicine. 9(6). s633–s633.
2.
Merola, Joseph F., Laura K. Ferris, Jeffrey M. Sobell, et al.. (2025). Deucravacitinib: Adverse Events of Interest Across Phase 3 Plaque Psoriasis Trials. Dermatology and Therapy. 15(2). 453–462. 1 indexed citations
3.
Armstrong, April W., Mark Lebwohl, Richard B. Warren, et al.. (2025). Deucravacitinib in plaque psoriasis: Four‐year safety and efficacy results from the Phase 3 POETYK PSO‐1, PSO‐2 and long‐term extension trials. Journal of the European Academy of Dermatology and Venereology. 39(7). 1336–1351. 8 indexed citations
4.
Bagel, Jerry, et al.. (2025). 62619 Efficacy and safety of tildrakizumab for the treatment of patients with moderate-to-severe plaque psoriasis and diabetes: Post hoc analysis of reSURFACE 1 and reSURFACE 2. Journal of the American Academy of Dermatology. 93(3). AB187–AB187. 1 indexed citations
5.
6.
Elewski, Boni E. & Mark Lebwohl. (2025). Management of Chronic Generalized Pustular Psoriasis: A Review and Expert Opinion. PubMed. 10(2). 58–66. 2 indexed citations
7.
Tan, Kathryn, et al.. (2025). Systemic Janus kinase inhibitors in the management of granuloma annulare. Archives of Dermatological Research. 317(1). 743–743.
8.
Krueger, James G., Chris Wynne, Mark Lebwohl, et al.. (2025). Phase 1 Clinical Data of ORKA-001, a Novel Half-Life Extended IL-23p19 Monoclonal Antibody with Potential for Once-Yearly Dosing in Plaque Psoriasis. SKIN The Journal of Cutaneous Medicine. 9(6). s634–s634.
9.
Sherer, Daniel, Lionel Bercovitch, & Mark Lebwohl. (2001). Pseudoxanthoma elasticum: Significance of limited phenotypic expression in parents of affected offspring. Journal of the American Academy of Dermatology. 44(3). 534–537. 48 indexed citations
10.
Lebwohl, Mark, et al.. (2001). Acne therapy: Clinical pearls. Seminars in Cutaneous Medicine and Surgery. 20(3). 184–189. 9 indexed citations
11.
Liu, Zhisong, Yuhun Lu, Mark Lebwohl, & Huachen Wei. (1999). PUVA (8-methoxy-psoralen plus ultraviolet A) induces the formation of 8-hydroxy-2′-deoxyguanosine and DNA fragmentation in calf thymus DNA and human epidermoid carcinoma cells. Free Radical Biology and Medicine. 27(1-2). 127–133. 40 indexed citations
12.
Kuroda, Kei, et al.. (1999). Interactions between tazarotene and ultraviolet light. Journal of the American Academy of Dermatology. 41(6). 927–930. 29 indexed citations
13.
Lebwohl, Mark. (1999). Acitretin in combination with UVB or PUVA. Journal of the American Academy of Dermatology. 41(3). S22–S24. 54 indexed citations
14.
Lebwohl, Mark, et al.. (1997). Interactions between calcipotriene and ultraviolet light. Journal of the American Academy of Dermatology. 37(1). 93–95. 54 indexed citations
15.
Phelps, Robert, et al.. (1997). Pyoderma gangrenosum associated with anticardiolipin antibodies in a pregnant patient. International Journal of Dermatology. 36(3). 205–207. 13 indexed citations
16.
See, Jo‐Ann, W Amend, Charles N. Ellis, et al.. (1996). Proceedings of the Psoriasis Combination and Rotation Therapy Conference. Journal of the American Academy of Dermatology. 34(2). 315–321. 51 indexed citations
17.
Prystowsky, Janet H., et al.. (1996). Infectious complications of erythrodermic psoriasis. Journal of the American Academy of Dermatology. 34(5). 911–914. 52 indexed citations
18.
Olsen, Elise A., David L. Cram, Charles N. Ellis, et al.. (1991). A double-blind, vehicle-controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis. Journal of the American Academy of Dermatology. 24(3). 443–447. 67 indexed citations
19.
Lebwohl, Mark, et al.. (1990). Determination of desmosines in elastin-related skin disorders by isocratic high-performance liquid chromatography. Experimental and Molecular Pathology. 52(1). 63–68. 24 indexed citations
20.
Lebwohl, Mark, Robert Phelps, Marsha Gordon, & Raúl Fleischmajer. (1990). Disease of the dermis. Journal of the American Academy of Dermatology. 23(2). 295–299. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tomotaka Mabuchi Breakdown of academic impact, for papers by Slaheddine Marrakchi Breakdown of academic impact, for papers by Satveer K. Mahil Breakdown of academic impact, for papers by Marco Galluzzo Breakdown of academic impact, for papers by M. Lahfa Breakdown of academic impact, for papers by Efterpi Zafiriou Breakdown of academic impact, for papers by Wojciech Baran Breakdown of academic impact, for papers by Inna Cueto Breakdown of academic impact, for papers by Nicoletta Bernardini Breakdown of academic impact, for papers by Dagmar Wilsmann‐Theis
Rankless by CCL
2026